BEST1 gene therapy corrects a diffuse retina-wide microdetachment modulated by light exposure
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Significance: One of the most common forms of monogenic macular degeneration worldwide is caused by dominant or recessive bestrophinopathies associated with mutations in the BEST1 gene. Disease expression is known to start with a retina-wide electrophysiological defect leading to localized vitelliform and atrophic lesions and vision loss. To develop lasting therapies for this incurable disease, there is a need for greater understanding of the early pathophysiology before lesion formation. Here we find that the loss of retinal pigment epithelium apical microvilli and resulting microdetachment of the retina represent the earliest features of canine bestrophinopathies. We show that retinal light exposure expands, and dark adaptation contracts, the microdetachments. Subretinal adeno-associated virus-based gene therapy corrects both the vitelliform lesions and the light-modulated microdetachments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chemistry of the Retinoid (Visual) Cycle
Kiser, P. D., Golczak, M., & Palczewski, K. (2014) · Chemical Reviews · doi:10.1021/cr400107q · Cited by 353 · cited 2×
“This number is even higher (∼50-fold) for the small RPE cells in the macular region (26, 61, 63) that adapted to a higher turnover rate of shed POS while facing the most densely packed PRs.”
BackgroundThe Cone-specific visual cycle
Wang, J.-S., & Kefalov, V. J. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.11.001 · Cited by 335
Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy
Cideciyan, A. V. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.04.002 · Cited by 256
Self-citationGhazi, N. G., Abboud, E. B., Nowilaty, S. R., Alkuraya, H., Alhommadi, A., Cai, H., Hou, R., Deng, W.-T., Boye, S. L., Almaghamsi, A., et al. (2016) · Human Genetics · doi:10.1007/s00439-016-1637-y · Cited by 243
Self-citationA comparison of some organizational characteristics of the mouse central retina and the human macula
Volland, S., Esteve-Rudd, J., Hoo, J., Yee, C., & Williams, D. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125631 · Cited by 229 · cited 1×
“This number is even higher (∼50-fold) for the small RPE cells in the macular region (26, 61, 63) that adapted to a higher turnover rate of shed POS while facing the most densely packed PRs.”
BackgroundIdentification of DES1 as a vitamin A isomerase in Müller glial cells of the retina
Kaylor, J. J., Yuan, Q., Cook, J., Sarfare, S., Makshanoff, J., Miu, A., Kim, A., Kim, P., Habib, S., Roybal, C. N., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1114 · Cited by 107
Light-evoked changes in the interphotoreceptor matrix
Uehara, F., Matthes, M. T., Yasumura, D., & LaVail, M. M. (1990) · Science · doi:10.1126/science.2194288 · Cited by 89
Optimization of Retinal Gene Therapy for X-Linked Retinitis Pigmentosa Due to RPGR Mutations
Beltran, W. A., Cideciyan, A. V., Boye, S. E., Ye, G.-J., Iwabe, S., Dufour, V. L., Marinho, L. F., Swider, M., Kosyk, M. S., Sha, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.004 · Cited by 82
Self-citation
Cited by
O’Koren, E. G., Yu, C., Klingeborn, M., Wong, A. Y. W., Prigge, C. L., Mathew, R., Kalnitsky, J., Msallam, R. A., Silvin, A., Kay, J. N., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.02.007 · Cited by 440
Mutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector
Cideciyan, A. V., Sudharsan, R., Dufour, V. L., Massengill, M. T., Iwabe, S., Swider, M., Lisi, B., Sumaroka, A., Marinho, L. F., Appelbaum, T., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805055115 · Cited by 147
“A slight increase in ONL thickness without any clinical evidence of inflammation, as seen in dogs injected with AAV-mediated gene therapy in other studies (76, 77), was also observed here in the treated areas.”
ResultSelf-citationLong-term Structural Outcomes of Late-stage RPE65 Gene Therapy
Gardiner, K. L., Cideciyan, A. V., Swider, M., Dufour, V. L., Sumaroka, A., Komáromy, A. M., Hauswirth, W. W., Iwabe, S., Jacobson, S. G., Beltran, W. A., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.013 · Cited by 67
Self-citationDaich Varela, M., Georgiadis, A., & Michaelides, M. (2023) · British Journal of Ophthalmology · doi:10.1136/bjo-2022-321903 · Cited by 30
Metadata
- Authors
- Guziewicz, K. E., Cideciyan, A. V., Beltran, W. A., Komáromy, A. M., Dufour, V. L., Swider, M., Iwabe, S., Sumaroka, A., Kendrick, B. T., Ruthel, G., Chiodo, V. A., Héon, E., Hauswirth, W. W., Jacobson, S. G., & Aguirre, G. D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2018-03-05
- Volume
- 115
- Issue
- 12
- Pages
- E2839-E2848
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2793264310
- Cited by
- 80
- References
- 8
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BEST1 gene therapy corrects a diffuse retina-wide microdetachment modulated by light exposure. https://app.cochat.ai/papers/10.1073/pnas.1720662115
- The paper
- Guziewicz, K. E., Cideciyan, A. V., Beltran, W. A., Komáromy, A. M., Dufour, V. L., Swider, M., Iwabe, S., Sumaroka, A., Kendrick, B. T., Ruthel, G., Chiodo, V. A., Héon, E., Hauswirth, W. W., Jacobson, S. G., & Aguirre, G. D. (2018). BEST1 gene therapy corrects a diffuse retina-wide microdetachment modulated by light exposure. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1720662115
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.